
    
      The study assesses multiple ascending doses of EDP-514 compared to placebo for 28 days in
      viremic chronic CHB-infected subjects not currently on treatment.

      Each cohort will enroll a total of 8 subjects who will be randomized to receive EDP-514 or
      placebo.
    
  